Yutaka Kohgo ¹, Toshifumi Ashida, Atsuo Maemoto, Tokiyoshi Ayabe, J Gastroenterol. 2003 Mar;38 Suppl 15:51-4.

The recent development of effective and safe devices to remove leukocytes selectively from circulating blood has facilitated the application of leukocytapheresis for the treatment of inflammatory bowel disease (IBD). Successful results of preliminary trials of leukocytapheresis for IBD led to several nationwide multicenter clinical trials in Japan. As a result, five or six consecutive leukocytaphereses, which were undergone weekly, improved both symptoms and endoscopic findings in approximately 60%-80% of patients with ulcerative colitis (UC). In Japan, leukocytapheresis is now considered to be one of the standard treatments for UC patients with refractory disease to avoid surgery. Here, the current status of indications and mechanisms of action on UC are analyzed by reviewing the results of Japanese multicicenter trials, and the possible application for Crohn’s disease is also discussed.

https://pubmed.ncbi.nlm.nih.gov/12698872/

Hiroyuki Hanai 1, Fumitoshi Watanabe, Ken Takeuchi, Takayuki Iida, Masami Yamada, Yasushi Iwaoka, Abby Saniabadi, Isao Matsushita, Yoshihiko Sato, Kotaro Tozawa, Hajime Arai, Takahisa Furuta, Ken Sugimoto, Ingvar Bjarnason, Clin Gastroenterol Hepatol. 2003 Jan;1(1):28-35.

The outcome of this study suggests that reduction of circulating granulocytes and monocytes results in alleviation of inflammation and promotes clinical remission in patients with severe active UC that has not responded to intensive corticosteroid treatment. These data suggest that formal controlled studies are warranted.

https://pubmed.ncbi.nlm.nih.gov/15017514/

Toshiyuki Matsui, Taku Nishimura, Hiroaki Matake, Tomohiro Ohta, Toshihiro Sakurai, Tsuneyoshi Yao, Am J Gastroenterol. 2003 Feb;98(2):511-2.

https://pubmed.ncbi.nlm.nih.gov/12591086/

Aki Hirayama ¹, Sohji Nagase, Atsushi Ueda, Takashi Ishizu, Yoshinori Taru, Keigyou Yoh, Kouichi Hirayama, Masaki Kobayashi, Akio Koyama, J Clin Apher. 2003;18(2):61-6.

These results indicate that though the plasma antioxidant activity was diminished by a column passage, plasma antioxidant activity recovers during the procedure. This efficient antioxidative effect is limited to the early phase of the therapeutic course.

https://pubmed.ncbi.nlm.nih.gov/12874817/

Koji Sawada, Kunio Ohnishi, Ken Fukunaga, Takashi Shimoyama, Am J Gastroenterol. 2003 Jan;98(1):228-9.

https://pubmed.ncbi.nlm.nih.gov/12526978/

Koji Sawada, Dis Colon Rectum. 2003 Oct;46(10 Suppl):S66-77.

 Clinical data suggest that leukocytapheresis might be an effective adjunct to therapy for inflammatory bowel disease to promote remission, taper conventional drug dosage, and potentially reduce the number of patients who require colectomy. The results should further understanding of the pathophysiology of inflammatory bowel disease.

https://pubmed.ncbi.nlm.nih.gov/14530661/

Yoshiyasu Tsuji ¹, Ryukichi Kumashiro, Kunihide Ishii, Teruko Arinaga, Yoshihiro Sakamoto, Ryo Tanabe, Kei Ogata, Yuriko Koga, Tatsuya Ide, Naofumi Ono, Eisuke Tanaka, Hirohiko Abe, Michio Sata, Alcohol Clin Exp Res. 2003 Aug;27(8 Suppl):26S-31S.

GCAP is recommended as a potential therapeutic option for severe alcoholic hepatitis.

https://pubmed.ncbi.nlm.nih.gov/12960503/

Yuriko Tsukada ¹, Tetsuo Nakamura, Mitsutoshi Iimura, Bun-ei Iizuka, Naoaki Hayashi, Am J Gastroenterol. 2002 Nov;97(11):2820-8.

IL-8 mRNA was significantly increased in inflamed mucosa of UC. Patients with high IL-8 mRNA expression in colonic mucosa despite PSL treatment were responsive to GCAP. Therefore, quantitative measurement of mucosal IL-8 mRNA may be useful in predicting the response to GCAP.

https://pubmed.ncbi.nlm.nih.gov/12425554/